Our results demonstrate that AML promotes leukaemogenesis in CD8+ T cells through the upregulation of multiple hallmark pathways and highlight the need for personalised medicine to target upregulated transcription factors and oncogenic signalling pathways for AML treatment. The gene discussed is CD8A; the disease is acute myeloid leukemia.